<?xml version="1.0" encoding="UTF-8"?><COCHRANE_REVIEW DESCRIPTION="Cochrane Support for publication" DOI="10.1002/14651858.CD015246.pub2" GROUP_ID="ENT" ID="122521080213284626" MERGED_FROM="" MODIFIED="2021-09-30 10:03:56 +0000" MODIFIED_BY="8773" REVIEW_NO="MENIERE4" REVMAN_SUB_VERSION="5.4.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="1.4"><COVER_SHEET MODIFIED="2021-08-02 13:28:49 +0000" MODIFIED_BY="6CC7734682E26AA2008F53C85074DEB8"><TITLE MODIFIED="2022-09-02 15:07:20 +0000" MODIFIED_BY="6CC7734682E26AA2008F53C85074DEB8">Intratympanic gentamicin for Ménière’s disease</TITLE><CONTACT><PERSON ID="5B1A013182E26AA200AF683A366CF7F3" MODIFIED="2023-02-06 16:06:48 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Katie</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Webster</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>katie.webster@nds.ox.ac.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Cochrane ENT</DEPARTMENT><ORGANISATION>Nuffield Department of Surgical Sciences, University of Oxford</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Oxford</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON></CONTACT><CREATORS MODIFIED="2023-02-06 16:06:48 +0000" MODIFIED_BY="8773"><PERSON ID="5B1A013182E26AA200AF683A366CF7F3" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Katie</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Webster</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>katie.webster@nds.ox.ac.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Cochrane ENT</DEPARTMENT><ORGANISATION>Nuffield Department of Surgical Sciences, University of Oxford</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Oxford</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z2001201455262583895685719757999" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Kevin</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Galbraith</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>kevin.galbraith@nds.ox.ac.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Cochrane ENT</DEPARTMENT><ORGANISATION>Nuffield Department of Surgical Sciences, University of Oxford</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Oxford</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z1603121652240273164429684157017" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Ambrose</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Lee</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>ambrose.w.lee@gmail.com</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of Otolaryngology - Head and Neck Surgery</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Toronto</CITY><ZIP/><REGION/><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z2108060943159876559960952123653" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Natasha</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Harrington-Benton</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>natasha@menieres.org.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT/><ORGANISATION>Ménière’s Society</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Wooton</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z2108060949094257247343818859942" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Owen</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Judd</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>owenjudd@doctors.org.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>ENT Department</DEPARTMENT><ORGANISATION>University Hospitals Of Derby and Burton NHS Foundation Trust</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Derby</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z2108060956464106027345580608301" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Diego</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Kaski</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>d.kaski@ucl.ac.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT/><ORGANISATION>National Hospital for Neurology and Neurosurgery</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>London</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z2108061001312325012751953194962" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Otto</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Maarsingh</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>o.maarsingh@amsterdamumc.nl</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of General Practice, Amsterdam UMC</DEPARTMENT><ORGANISATION>Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Amsterdam</CITY><ZIP/><REGION/><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z2005041451280480946175458053440" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Samuel</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>MacKeith</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>samuel.mackeith@ouh.nhs.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>ENT Department</DEPARTMENT><ORGANISATION>Oxford University Hospitals NHS Foundation Trust</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Oxford</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z2108061004302876403594766694595" MODIFIED="2023-02-25 17:46:31 +0000" MODIFIED_BY="z1902121354153310728822207704342" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Jaydip</FIRST_NAME><MIDDLE_INITIALS/><LAST_NAME>Ray</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>jaydip.ray1@nhs.net</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT/><ORGANISATION>University of Sheffield</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Sheffield</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="z2108061007305939699013315739257" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Vincent</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Van Vugt</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>v.vanvugt@amsterdamumc.nl</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT>Department of General Practice, Amsterdam UMC</DEPARTMENT><ORGANISATION>Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Amsterdam</CITY><ZIP/><REGION/><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON><PERSON ID="BE67C2AB82E26AA2014A5594476783BD" MODIFIED="2023-02-06 16:06:49 +0000" MODIFIED_BY="8773" ROLE="AUTHOR"><PREFIX/><FIRST_NAME>Martin</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Burton</LAST_NAME><SUFFIX/><POSITION/><EMAIL_1>martin.burton@cochrane.nhs.uk</EMAIL_1><EMAIL_2/><URL/><MOBILE_PHONE/><ADDRESS><DEPARTMENT/><ORGANISATION>Cochrane UK</ORGANISATION><ADDRESS_1/><ADDRESS_2/><CITY>Oxford</CITY><ZIP/><REGION/><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1/><PHONE_2/><FAX_1/><FAX_2/></ADDRESS><FOOTNOTE/></PERSON></CREATORS><DATES MODIFIED="2023-02-25 17:46:31 +0000" MODIFIED_BY="z1902121354153310728822207704342"><UP_TO_DATE><DATE DAY="" MONTH="" YEAR=""/></UP_TO_DATE><LAST_SEARCH><DATE DAY="14" MONTH="9" YEAR="2022"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="" MONTH="" YEAR=""/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="12" YEAR="2021"/><REVIEW_PUBLISHED ISSUE="" YEAR=""/><LAST_CITATION_ISSUE ISSUE="12" YEAR="2021"/></DATES><WHATS_NEW/><HISTORY/><SOURCES_OF_SUPPORT MODIFIED="2021-08-02 13:28:49 +0000" MODIFIED_BY="6CC7734682E26AA2008F53C85074DEB8"><INTERNAL_SOURCES/><EXTERNAL_SOURCES/></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT><SUMMARY><TITLE/><SUMMARY_BODY/></SUMMARY><ABSTRACT><ABS_BACKGROUND/><ABS_OBJECTIVES/><ABS_SEARCH_STRATEGY/><ABS_SELECTION_CRITERIA/><ABS_DATA_COLLECTION/><ABS_RESULTS/><ABS_CONCLUSIONS/></ABSTRACT><BODY><BACKGROUND><CONDITION/><INTERVENTION/><THEORY/><IMPORTANCE/></BACKGROUND><OBJECTIVES/><METHODS><SELECTION_CRITERIA><CRIT_STUDIES/><CRIT_PARTICIPANTS/><CRIT_INTERVENTIONS/><CRIT_OUTCOMES><CRIT_OUTCOMES_PRIMARY/><CRIT_OUTCOMES_SECONDARY/></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS><ELECTRONIC_SEARCHES/><OTHER_SEARCHES/></SEARCH_METHODS><DATA_COLLECTION><STUDY_SELECTION/><DATA_EXTRACTION/><QUALITY_ASSESSMENT/><EFFECT_MEASURES/><UNIT_OF_ANALYSIS/><MISSING_DATA/><HETEROGENEITY_ASSESSMENT/><BIAS_ASSESSMENT/><DATA_SYNTHESIS/><SUBGROUP_ANALYSIS/><SENSITIVITY_ANALYSIS/></DATA_COLLECTION></METHODS><RESULTS><STUDY_DESCRIPTION><SEARCH_RESULTS/><INCLUDED_STUDIES_DESCR/><EXCLUDED_STUDIES_DESCR/></STUDY_DESCRIPTION><STUDY_QUALITY><ALLOCATION/><BLINDING/><EXCLUSIONS/><SELECTIVE_REPORTING/><OTHER_BIAS_SOURCES/></STUDY_QUALITY><INTERVENTION_EFFECTS/></RESULTS><DISCUSSION><SUMMARY_OF_RESULTS/><APPLICABILITY_OF_FINDINGS/><QUALITY_OF_EVIDENCE/><POTENTIAL_BIASES/><AGREEMENT/></DISCUSSION><CONCLUSIONS><IMPLICATIONS_PRACTICE/><IMPLICATIONS_RESEARCH/></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS/><CONFLICT_OF_INTEREST/><CONTRIBUTIONS/><PRO_REV_DIFF/><PUBLIC_NOTES/></MAIN_TEXT><STUDIES_AND_REFERENCES><STUDIES><INCLUDED_STUDIES><STUDY DATA_SOURCE="PUB" ID="STD-Bremer-2014" NAME="Bremer 2014" YEAR="2014"><IDENTIFIERS/></STUDY><STUDY DATA_SOURCE="PUB" ID="STD-Choudhary-2019" NAME="Choudhary 2019" YEAR="2019"><IDENTIFIERS/></STUDY><STUDY DATA_SOURCE="PUB" ID="STD-Postema-2008" NAME="Postema 2008" YEAR="2008"><IDENTIFIERS/></STUDY><STUDY DATA_SOURCE="PUB" ID="STD-Stokroos-2004" NAME="Stokroos 2004" YEAR="2004"><IDENTIFIERS/></STUDY><STUDY DATA_SOURCE="PUB" ID="STD-Ul-Shamas-2017" NAME="Ul Shamas 2017" YEAR="2017"><IDENTIFIERS/></STUDY></INCLUDED_STUDIES><EXCLUDED_STUDIES/><AWAITING_STUDIES/><ONGOING_STUDIES/></STUDIES><OTHER_REFERENCES><ADDITIONAL_REFERENCES/><OTHER_VERSIONS_REFERENCES/><PENDING_REFERENCES/></OTHER_REFERENCES></STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES><CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Funding sources" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Declarations of interest" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR STUDY_ID="STD-Bremer-2014"><CHAR_METHODS/><CHAR_PARTICIPANTS/><CHAR_INTERVENTIONS/><CHAR_OUTCOMES/><CHAR_USER_DEF_1/><CHAR_USER_DEF_2/><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR STUDY_ID="STD-Choudhary-2019"><CHAR_METHODS/><CHAR_PARTICIPANTS/><CHAR_INTERVENTIONS/><CHAR_OUTCOMES/><CHAR_USER_DEF_1/><CHAR_USER_DEF_2/><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR STUDY_ID="STD-Postema-2008"><CHAR_METHODS/><CHAR_PARTICIPANTS/><CHAR_INTERVENTIONS/><CHAR_OUTCOMES/><CHAR_USER_DEF_1/><CHAR_USER_DEF_2/><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR STUDY_ID="STD-Stokroos-2004"><CHAR_METHODS/><CHAR_PARTICIPANTS/><CHAR_INTERVENTIONS/><CHAR_OUTCOMES/><CHAR_USER_DEF_1/><CHAR_USER_DEF_2/><CHAR_NOTES/></INCLUDED_CHAR><INCLUDED_CHAR STUDY_ID="STD-Ul-Shamas-2017"><CHAR_METHODS/><CHAR_PARTICIPANTS/><CHAR_INTERVENTIONS/><CHAR_OUTCOMES/><CHAR_USER_DEF_1/><CHAR_USER_DEF_2/><CHAR_NOTES/></INCLUDED_CHAR><FOOTNOTES/></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY"/><CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"/><CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"/></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2023-02-06 15:53:30 +0000" MODIFIED_BY="8773"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2023-02-06 15:53:30 +0000" MODIFIED_BY="8773" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-05 12:17:52 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="YES" STUDY_ID="STD-Bremer-2014"><DESCRIPTION><P>Quote: "For assignment of the participants a computer-generated list of random numbers was used".</P><P>Comment: adequate randomisation method. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-05 10:35:03 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Choudhary-2019"><DESCRIPTION><P>Quote: "We numbered the patients who qualified for our study depending upon the inclusion criteria &amp; then used random number table to assign patients into intervention group &amp; control group". "Patients were free to consent for the intervention &amp; if any one did not give consent, he/she was put into the control group &amp; the next patient was considered for placement in intervention group."</P><P>Comment: true randomisation was conducted initially using a random number table. However, if those allocated to the intervention group did not give subsequent consent, they were added to the control group. The "next" participant was then placed in the intervention group, presumably to achieve a balance in numbers across groups. This could be considered quasi-randomisation. There is considerable risk that a balance of important prognostic factors (especially those that might be associated with a preference not to provide consent) may not have been achieved across groups. No baseline characteristics were provided for each group, making it difficult to judge whether such balance had been achieved. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-06 10:49:04 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Postema-2008"><DESCRIPTION><P>Quote: "prospective, double-blind, randomized, placebo-controlled clinical trial". </P><P>Comment: no information on methods of randomisation are reported. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-06 11:55:33 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Stokroos-2004"><DESCRIPTION><P>Quote: "Randomization was performed by the hospital pharmacist, who was the only person who knew whether placebo or gentamicin was given before the end of the study period". </P><P>Comment: insufficient information was given about sequence generation. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-05-17 08:20:36 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Ul-Shamas-2017"><DESCRIPTION><P>Quote: "60 consecutive patients of Meniere’s disease were randomly divided into 3 groups of twenty patients each."</P><P>Comment: very limited information regarding randomisation. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2023-02-06 15:53:30 +0000" MODIFIED_BY="8773" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-05 12:18:28 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Bremer-2014"><DESCRIPTION><P>Quote: "For assignment of the participants a computer-generated list of random numbers was used". </P><P>Comment: no details regarding concealment of the list of random numbers. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-05 10:36:15 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Choudhary-2019"><DESCRIPTION><P>Quote: "Patients were free to consent for the intervention &amp; if any one did not give consent, he/she was put into the control group &amp; the next patient was considered for placement in intervention group."</P><P>Comment: allocation was not concealed, and participant could choose to change groups if they required. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-06 10:49:30 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Postema-2008"><DESCRIPTION><P>Quote: "During the final visit the double-blind code was broken. Before that time this code was only known to one of the hospital pharmacists". </P><P>Comment: no details on how the code was secured. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-06 11:56:06 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Stokroos-2004"><DESCRIPTION><P>Quote: "Randomization was performed by the hospital pharmacist, who was the only person who knew whether placebo or gentamicin was given before the end of the study  period". </P><P>Comment: no details provided on how allocation was concealed. Concern over baseline imbalance in vertigo frequency, which could indicate that people with worse symptoms were preferentially recruited to the gentamicin group. However, this would potentially bias the effect size towards the null. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-05-17 08:20:44 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Ul-Shamas-2017"><DESCRIPTION><P>Comment: no details regarding methods used to ensure group allocation was concealed. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2023-02-06 15:53:30 +0000" MODIFIED_BY="8773" NO="3"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2022-04-05 12:21:51 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Bremer-2014"><DESCRIPTION><P>Quote: From trial protocol: "Neither the investigator, nor the treating physician, nor the subject is aware of the sequence for randomization." "After ITG treatment patients were advised to visit the physiotherapist for, for example, Cawthorn-Cooksey exercises or other patient-specific exercises."</P><P>Comment: although the intention was for the trial to be double-blind, there is a suggestion in the article that participants in the intratympanic gentamicin groups had access to a physiotherapist if required, and it is not clear if this was also offered to the placebo group. Therefore, there is the potential for blinding to have been compromised. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2022-04-05 10:37:00 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Choudhary-2019"><DESCRIPTION><P>Comment: no blinding of participants (allocation was to an active intervention or no treatment). </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2022-04-06 10:50:04 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="YES" STUDY_ID="STD-Postema-2008"><DESCRIPTION><P>Quote: "During the final visit the double-blind code was broken. Before that time this code was only known to one of the hospital pharmacists."</P><P>Comment: lack of detail, but study is described as double-blind, and it is likely that participants would have been unable to tell if they were receiving active treatment or placebo. Article indicates that study personnel were blinded (see quote above). </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2022-04-06 11:56:34 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="YES" STUDY_ID="STD-Stokroos-2004"><DESCRIPTION><P>Quote: "Randomization was performed by the hospital pharmacist, who was the only person who knew whether placebo or gentamicin was given before the end of the study  period". </P><P>Comment: all parties involved in the trial except the hospital pharmacist were blind to treatment allocation.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2022-05-17 08:20:46 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Ul-Shamas-2017"><DESCRIPTION><P>Comment: open-label study. No blinding was used. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2023-02-06 15:53:30 +0000" MODIFIED_BY="8773" NO="4"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2022-04-05 12:25:22 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Bremer-2014"><DESCRIPTION><P>Quote: From trial protocol: "Neither the investigator, nor the treating physician, nor the subject is aware of the sequence for randomization." "After ITG treatment patients were advised to visit the physiotherapist for, for example, Cawthorn-Cooksey exercises or other patient-specific exercises."</P><P>Comment: although the intention was for the trial to be double-blind, there is a suggestion in the article that participants in the intratympanic gentamicin groups had access to a physiotherapist if required, and it is not clear if this was also offered to the placebo group. Therefore, there is the potential for blinding to have been compromised. Primary outcome was reported by participants themselves. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2022-04-05 10:37:38 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Choudhary-2019"><DESCRIPTION><P>Comment: outcome measures were reported by unblinded participants. The measurement of all outcomes could have been influenced by knowledge of group assignation. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2022-04-06 10:50:50 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Postema-2008"><DESCRIPTION><P>Quote: "During the final visit the double-blind code was broken. Before that time this code was only known to one of the hospital pharmacists."</P><P>Comment: the nature of the outcomes was such that measurement could be subject to bias given knowledge of the assigned group. Blinding was described as 'double' but few further details were provided. Blinding was 'broken' at 12 months post-treatment. This was stated to be <U>during</U> the final visit, suggesting that participants and personnel were made aware of group allocation during this visit. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2022-04-06 11:57:05 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="YES" STUDY_ID="STD-Stokroos-2004"><DESCRIPTION><P>Quote: "Randomization was performed by the hospital pharmacist, who was the only person who knew whether placebo or gentamicin was given before the end of the study period". </P><P>Comment: all parties involved in the trial except the hospital pharmacist were blind to treatment allocation. Outcomes were reported by blinded participants. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2022-05-17 08:20:56 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Ul-Shamas-2017"><DESCRIPTION><P>Comment: open-label trial. No blinding of outcome assessors was reported. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="GROUP" MODIFIED="2023-02-06 15:53:30 +0000" MODIFIED_BY="8773" NO="5"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-05.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2022-04-05 12:26:26 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Bremer-2014"><DESCRIPTION><P>Comment: few participants and unequal dropout between groups, with loss to follow-up predominantly in the low-dose gentamicin group (2/5 participants). This is likely to have influenced the results. <BR/>One patient (group 2) withdrew from the study after randomisation because she did not want placebo. This reason for withdrawal is unlikely to be related to the true outcomes (DHI score and hearing change). Another patient (group not reported) withdrew from the study after 2 injections because he suffered from Tumarkins crises. This reason for withdrawal is likely to be related to the true outcome for DHI score. One patient (group 2) died during the study as a result of co-morbidity. This is unlikely to be related to the true outcomes (DHI score and hearing change). Therefore, for 1 of the 3 losses to follow-up, the reason for withdrawal was likely to be related to the putative true outcome. Furthermore, given the small number of participants, 2 losses from group 2 (40%) is likely to exert a differential potential for bias across groups.  </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2022-04-05 10:38:56 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="YES" STUDY_ID="STD-Choudhary-2019"><DESCRIPTION><P>Comment: complete follow-up is reported with no attrition. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2022-04-06 10:52:52 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="YES" STUDY_ID="STD-Postema-2008"><DESCRIPTION><P>Comment: dropout is comparatively low (2/28 participants), although both dropouts were in the placebo group, and no information was provided regarding the cause for dropout. Dropout is probably not large enough to have a meaningful impact on the estimated effect size.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2022-04-06 11:57:24 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="YES" STUDY_ID="STD-Stokroos-2004"><DESCRIPTION><P>Comment: no missing data are reported. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-05.01" MODIFIED="2022-05-17 08:21:29 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Ul-Shamas-2017"><DESCRIPTION><P>Comment: no details provided on attrition/exclusions from the study. It is possible that hearing and tinnitus outcome data were either not measured, or not reported for participants who did not have hearing loss or tinnitus at the start of the study: "Patients with hearing loss underwent PTA before treatment and 2 weeks and 6 months post intra tympanic medication." "Patients with tinnitus were graded using tinnitus handicap inventory before and after treatment". (Note that only 52 of the 60 trial participants had tinnitus at the start of the study, and their group assignments were not reported). This could affect interpretation of the rate of profound sensorineural hearing loss among this treated with intratympanic gentamicin. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2023-02-06 15:53:30 +0000" MODIFIED_BY="8773" NO="6"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-05 12:27:18 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Bremer-2014"><DESCRIPTION><P>Comment: protocol indicates that a number of additional outcomes will be assessed, but these are not reported, including control of vertigo, ABC scale, THI, electronystagmography and rescue medication. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-05 10:39:24 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Choudhary-2019"><DESCRIPTION><P>Comment: no protocol was available for comparison. However, information for some outcomes was reported incompletely and for only one intervention arm. A specified aim of the study was to compare groups for the degree of sensorineural hearing loss. However, the degree of hearing loss was not described and the outcome was presented dichotomised into "further hearing loss" and "no further hearing loss".</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-06 10:53:44 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Postema-2008"><DESCRIPTION><P>Comment: no protocol was available to assess whether all pre-specified outcomes were reported. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-06 11:57:47 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Stokroos-2004"><DESCRIPTION><P>Comment: results state that the number of vertiginous attacks was 0 for all participants in the gentamicin group. Discussion states that a recurrence of vertigo attacks occurred in 1 participant 1 to 2 years after successful ablation. No information on timing of outcome assessment. Some outcomes were described in the methods section, but not reported among the results: subjective hearing changes and speech audiometry.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-05-17 08:21:39 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Ul-Shamas-2017"><DESCRIPTION><P>Comment: no published protocol or trial registration. Study does not apparently assess any vertigo outcomes, which would be considered key for Ménière's disease. Reporting of some outcomes was incomplete - for example, the mean post-treatment PTA for group B (intratympanic dexamethasone) was not reported; the rate of sensorineural hearing loss was not reported for groups B and C (intratympanic dexamethasone and saline respectively).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-07" LEVEL="STUDY" MODIFIED="2023-02-06 15:53:30 +0000" MODIFIED_BY="8773" NO="7"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-05 12:28:12 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="YES" STUDY_ID="STD-Bremer-2014"><DESCRIPTION><P>Comment: no other potential source of bias was detected. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-05 10:41:37 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="UNKNOWN" STUDY_ID="STD-Choudhary-2019"><DESCRIPTION><P>Comment: limited details are presented regarding the study methods. It is unclear how participants recorded their vertigo episodes during the follow-up period. Methods of assessment for hearing loss were not described. </P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-06 10:54:14 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Postema-2008"><DESCRIPTION><P>Comment: unvalidated scales used for all outcome measures (except hearing). Unclear if participants assessed their symptoms over a given period of time, or simply on the day of their appointment - the authors do not report the use of a symptom diary.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-04-06 11:58:35 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Stokroos-2004"><DESCRIPTION><P>Comment: unclear how participants assessed vertigo frequency. Varying number of interventions in different participants, which may lead to differential period of follow-up between the 2 groups. No detail is given on the measurement of outcomes in terms of the precise methods, personnel involved, their training and the reliability of measurements.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2022-05-17 08:21:45 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" RESULT="NO" STUDY_ID="STD-Ul-Shamas-2017"><DESCRIPTION><P>Comment: very limited details provided regarding the nature and conduct of the study. Single author RCT with short period of recruitment for 60 participants in a single centre. The training and reliability of personnel assessing outcomes, and the validity of the instruments used, were not reported. No detail was provided on how many participants had unilateral/bilateral disease, and nor was the unit of analysis (person/ear) clarified. There was also a lack of data that could be used to compare outcomes across groups.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES/><ADDITIONAL_TABLES/><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2022-09-05 11:49:02 +0000" MODIFIED_BY="8773"><COMPARISON ID="CMP-001" MODIFIED="2022-09-05 11:49:02 +0000" MODIFIED_BY="8773" NO="1"><NAME>Intratympanic gentamicin versus no treatment/placebo</NAME><DICH_OUTCOME CHI2="12.730327865409173" CI_END="2.9476320019026607" CI_START="1.0947579152348796" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.796369523589891" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="6" I2="92.14474277039479" I2_Q="77.82077390113565" ID="CMP-001.01" LOG_CI_END="0.4694732629322743" LOG_CI_START="0.039318093878234144" LOG_EFFECT_SIZE="0.2543956784052543" METHOD="MH" MODIFIED="2022-07-19 11:41:16 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="1" P_CHI2="3.5977554161714664E-4" P_Q="0.03372244505821531" P_Z="0.02043504178309704" Q="4.508723593611785" RANDOM="YES" SCALE="600.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="11.782955909801924" TOTALS="SUB" TOTAL_1="28" TOTAL_2="26" WEIGHT="200.0" Z="2.3182628194073507"><NAME>Improvement in vertigo frequency</NAME><GROUP_LABEL_1>IT gentamicin</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours IT gentamicin</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="506.99574914672456" CI_START="2.147947003170717" DF="0" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="2.7050043180515604" LOG_CI_START="0.3320235617042143" LOG_EFFECT_SIZE="1.5185139398778875" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="1" P_CHI2="1.0" P_Z="0.012126767016687514" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="2.5084338541066815"><NAME>6 to ≤ 12 months</NAME><DICH_DATA CI_END="506.99574914672456" CI_START="2.147947003170717" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.7050043180515604" LOG_CI_START="0.3320235617042143" LOG_EFFECT_SIZE="1.5185139398778875" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" ORDER="1" O_E="0.0" SE="1.3939006427226193" STUDY_ID="STD-Choudhary-2019" TOTAL_1="16" TOTAL_2="16" VAR="1.9429590017825313" WEIGHT="100.0"><FOOTNOTE>AAO HNS 1995 class A, B or C (complete, substantial or limited improvement). Data from 6 months. </FOOTNOTE></DICH_DATA></DICH_SUBGROUP><DICH_SUBGROUP CHI2="0.0" CI_END="2.692444710373781" CI_START="0.9834339223129637" DF="0" EFFECT_SIZE="1.6272189349112427" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.4301467937801897" LOG_CI_START="-0.007254815347011447" LOG_EFFECT_SIZE="0.21144598921658914" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="2" P_CHI2="1.0" P_Z="0.05809936905799938" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="1.8949474116792273"><NAME>&gt; 12 months</NAME><DICH_DATA CI_END="2.692444710373781" CI_START="0.9834339223129637" EFFECT_SIZE="1.6272189349112427" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.4301467937801897" LOG_CI_START="-0.007254815347011447" LOG_EFFECT_SIZE="0.21144598921658914" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" ORDER="2" O_E="0.0" SE="0.25693187037420256" STUDY_ID="STD-Stokroos-2004" TOTAL_1="12" TOTAL_2="10" VAR="0.06601398601398603" WEIGHT="100.0"><FOOTNOTE>Participant reported "no vertigo", "significant reduction" or "some reduction". </FOOTNOTE></DICH_DATA></DICH_SUBGROUP></DICH_OUTCOME><DICH_OUTCOME CHI2="1.1073278916593963" CI_END="37.20096466843285" CI_START="2.7143689568284985" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="10.048738411366271" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="1" I2="9.692512260172466" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.570554201837415" LOG_CI_START="0.433668879810073" LOG_EFFECT_SIZE="1.002111540823744" METHOD="MH" MODIFIED="2022-05-10 11:59:21 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="2" P_CHI2="0.2926635775721814" P_Q="0.33112999527834996" P_Z="5.498149885889904E-4" Q="0.9444742622777673" RANDOM="YES" SCALE="600.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13532938981079717" TOTALS="SUB" TOTAL_1="28" TOTAL_2="26" WEIGHT="200.0" Z="3.455234209557755"><NAME>Improvement in vertigo frequency: sensitivity analysis for complete/substantial improvement</NAME><GROUP_LABEL_1>IT gentamicin</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours IT gentamicin</GRAPH_LABEL_2><DICH_SUBGROUP CHI2="0.0" CI_END="506.99574914672456" CI_START="2.147947003170717" DF="0" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="2.7050043180515604" LOG_CI_START="0.3320235617042143" LOG_EFFECT_SIZE="1.5185139398778875" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="1" P_CHI2="1.0" P_Z="0.012126767016687514" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="2.5084338541066815"><NAME>6 to ≤ 12 months</NAME><DICH_DATA CI_END="506.99574914672456" CI_START="2.147947003170717" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.7050043180515604" LOG_CI_START="0.3320235617042143" LOG_EFFECT_SIZE="1.5185139398778875" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" ORDER="3" O_E="0.0" SE="1.3939006427226193" STUDY_ID="STD-Choudhary-2019" TOTAL_1="16" TOTAL_2="16" VAR="1.9429590017825313" WEIGHT="100.0"><FOOTNOTE>AAO HNS 1995 class A or B (complete or substantial improvement). Data from 6 months. </FOOTNOTE></DICH_DATA></DICH_SUBGROUP><DICH_SUBGROUP CHI2="8.517772640640456E-32" CI_END="31.323639079691766" CI_START="1.587318077578287" DF="0" EFFECT_SIZE="7.051282051282052" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" I2="100.0" ID="CMP-001.02.02" LOG_CI_END="1.4958722112537544" LOG_CI_START="0.20066396235377273" LOG_EFFECT_SIZE="0.8482680868037635" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="2" P_CHI2="0.0" P_Z="0.010250264628917455" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="10" WEIGHT="100.0" Z="2.5672703996165795"><NAME>&gt; 12 months</NAME><DICH_DATA CI_END="31.323639079691766" CI_START="1.587318077578287" EFFECT_SIZE="7.051282051282051" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="1.4958722112537544" LOG_CI_START="0.20066396235377273" LOG_EFFECT_SIZE="0.8482680868037634" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" ORDER="4" O_E="0.0" SE="0.7608117367880827" STUDY_ID="STD-Stokroos-2004" TOTAL_1="12" TOTAL_2="10" VAR="0.5788344988344988" WEIGHT="100.0"><FOOTNOTE>Participant reported "no vertigo" or "significant reduction". </FOOTNOTE></DICH_DATA></DICH_SUBGROUP></DICH_OUTCOME><CONT_OUTCOME CHI2="2.630929869275673" CI_END="-0.9138104396738707" CI_START="-1.8804672878604547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.3971388637671627" ESTIMABLE="YES" I2="61.990625000000016" I2_Q="61.990625000000016" ID="CMP-001.03" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="3" P_CHI2="0.10480037182660873" P_Q="0.10480037182660873" P_Z="1.4651742805749139E-8" Q="2.630929869275673" RANDOM="YES" SCALE="3.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.19837" TOTALS="SUB" TOTAL_1="32" TOTAL_2="20" UNITS="" WEIGHT="200.0" Z="5.665592416837246"><NAME>Change in vertigo (global score)</NAME><GROUP_LABEL_1>IT gentamicin</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IT gentamicin</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_SUBGROUP CHI2="0.0" CI_END="-0.31890194010919204" CI_START="-1.6810980598908078" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="1" P_CHI2="1.0" P_Z="0.004006453697153925" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="10" WEIGHT="100.0" Z="2.8776531603309383"><NAME>6 to ≤ 12 months</NAME><CONT_DATA CI_END="-0.31890194010919204" CI_START="-1.6810980598908078" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="0.73" MEAN_2="1.73" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" ORDER="5" SD_1="0.72" SD_2="0.94" SE="0.3475053956415641" STUDY_ID="STD-Postema-2008" TOTAL_1="16" TOTAL_2="10" WEIGHT="100.0"><FOOTNOTE>Ordinal data, range 0 (no vertigo) to 3 (severe vertigo)</FOOTNOTE></CONT_DATA></CONT_SUBGROUP><CONT_SUBGROUP CHI2="0.0" CI_END="-1.1140126054109811" CI_START="-2.485987394589019" DF="0" EFFECT_SIZE="-1.8" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" NO="2" P_CHI2="1.0" P_Z="2.7059138193989065E-7" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="10" WEIGHT="100.0" Z="5.142857142857143"><NAME>&gt; 12 months</NAME><CONT_DATA CI_END="-1.1140126054109811" CI_START="-2.485987394589019" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="1.8" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" ORDER="6" SD_1="0.6" SD_2="1.0" SE="0.35" STUDY_ID="STD-Postema-2008" TOTAL_1="16" TOTAL_2="10" WEIGHT="100.0"><FOOTNOTE>Ordinal data, range 0 (no vertigo) to 3 (severe vertigo)</FOOTNOTE></CONT_DATA></CONT_SUBGROUP></CONT_OUTCOME><CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2022-09-05 11:49:02 +0000" MODIFIED_BY="8773" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="12" TOTAL_2="10" UNITS="" WEIGHT="0.0" Z="0.0"><NAME>Change in vertigo (frequency) &gt; 12 months</NAME><GROUP_LABEL_1>IT gentamicin</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IT gentamicin</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="11.0" MODIFIED="2022-07-01 11:41:33 +0000" MODIFIED_BY="z1603121652240273164429684157017" ORDER="7" SD_1="0.0" SD_2="10.0" SE="0.0" STUDY_ID="STD-Stokroos-2004" TOTAL_1="12" TOTAL_2="10" WEIGHT="0.0"><FOOTNOTE>Number of vertigo attacks per year. </FOOTNOTE></CONT_DATA></CONT_OUTCOME><CONT_OUTCOME CHI2="1.773082445340648" CI_END="15.685242375034147" CI_START="-8.291198741019578" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.697021817007284" ESTIMABLE="YES" I2="43.60104333400706" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2022-09-05 11:49:02 +0000" MODIFIED_BY="8773" NO="5" P_CHI2="0.18300118812351918" P_Q="1.0" P_Z="0.5455583830197732" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="36.27824810606055" TOTALS="YES" TOTAL_1="28" TOTAL_2="21" UNITS="" WEIGHT="100.0" Z="0.6044291207623335"><NAME>Change in hearing at &gt; 12 months</NAME><GROUP_LABEL_1>IT gentamicin</GROUP_LABEL_1><GROUP_LABEL_2>Control</GROUP_LABEL_2><GRAPH_LABEL_1>Favours IT gentamicin</GRAPH_LABEL_1><GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2><CONT_DATA CI_END="16.978479024853335" CI_START="-0.7784790248533362" EFFECT_SIZE="8.1" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="0.0" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" ORDER="8" SD_1="18.1" SD_2="0.7" SE="4.52991947550345" STUDY_ID="STD-Postema-2008" TOTAL_1="16" TOTAL_2="11" WEIGHT="65.86838617835103"><FOOTNOTE>Change from baseline. Assessed at approximately 13 months. </FOOTNOTE></CONT_DATA><CONT_DATA CI_END="11.984128818149486" CI_START="-21.58412881814948" EFFECT_SIZE="-4.799999999999997" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="58.8" MODIFIED="2022-04-25 19:31:42 +0000" MODIFIED_BY="5B1A013182E26AA200AF683A366CF7F3" ORDER="9" SD_1="20.0" SD_2="20.0" SE="8.563488385776754" STUDY_ID="STD-Stokroos-2004" TOTAL_1="12" TOTAL_2="10" WEIGHT="34.13161382164897"><FOOTNOTE>Endpoint data. Assessed at final follow-up, ranging from 6 to 28 months. </FOOTNOTE></CONT_DATA></CONT_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES/><FEEDBACK/><APPENDICES/><EXTENSIONS/></COCHRANE_REVIEW>